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C5L2 is a new cellular receptor found to interact with the
human anaphylatoxins complement factor C5a and its C-ter-
minal cleavage product C5a des Arg. The classical human C5a
receptor (C5aR) preferentially binds C5a, with a 10–100-fold
lower affinity for C5a des Arg. In contrast, C5L2 binds both
ligands with nearly equal affinity. C5aR presents acidic and
tyrosine residues in its N terminus that interact with the core
of C5a while a hydrophobic pocket formed by the transmem-
brane helices interacts with residues in the C terminus of C5a.
Here, we have investigated the molecular basis for the
increased affinity of C5L2 for C5a des Arg. Rat and mouse
C5L2 preferentially bound C5a des Arg, whereas rodent C5aR
showedmuch higher affinity for intact C5a. Effective peptidic
and non-peptidic ligands for the transmembrane hydropho-
bic pocket of C5aR were poor inhibitors of ligand binding to
C5L2. An antibody raised against the N terminus of human
C5L2 did not affect the binding of C5a to C5L2 but did inhibit
C5a des Arg binding. A chimeric C5L2, containing the N ter-
minus of C5aR, had little effect on the affinity for C5a des Arg.
Mutation of acidic and tyrosine residues in the N terminus of
human C5L2 revealed that 3 residues were critical for C5a des
Arg binding but had little involvement in C5a binding. C5L2
thus appears to bind C5a and C5a des Arg by different mech-
anisms, and, unlike C5aR, C5L2 uses critical residues in its
N-terminal domain for binding only to C5a des Arg.
Complement fragment 5a (C5a) is a 74-residue polypeptide
that is amultifunctional proinflammatorymediator that causes
leukocyte chemoattraction and degranulation, increases vascu-
lar permeability, and stimulates cytokine secretion (1). The
C-terminal Arg is rapidly cleaved in vivo to formC5a des Arg, a
plasma-stablemetabolite that has a different spectrum of activ-
ities than intact C5a (2). The classical receptor for C5a (C5aR) is
a member of the G protein-coupled receptor superfamily (3, 4)
and has high affinity for intact C5a but 10–100-fold lower affin-
ity for C5a des Arg (5). The receptor N terminus is required for
high affinity binding of C5a but not for receptor activation (6,
7): a series of acidic and oxygen-sulfated tyrosine residues inter-
act with basic residues in the core of C5a (8, 9). A second dis-
tinct binding site is formed by charged residues in the second
and third extracellular loops and the external faces of the trans-
membrane helical bundle and hydrophobic residues in the core
of the receptor (10). This site is responsible for receptor activa-
tion and is the target for agonist and antagonist peptidicmimics
of the C terminus of C5a (11). The second C5a receptor to be
discovered, C5L2, does not appear to couple to G proteins
and appears to have an anti-inflammatory function, balanc-
ing the pro-inflammatory role of C5aR (12–14). The mech-
anism of the anti-inflammatory effect is not known but may
be related to the ligand binding properties of C5L2, which
has nearly equal affinities for C5a and C5a des Arg. C5L2 has
41% sequence identity with C5aR (15), with a similar array of
acidic and tyrosine residues at the N terminus, and many of
the charged and hydrophobic residues in the loops and
transmembrane regions of C5aR that are involved in the
interaction with the C terminus of C5a are also conserved in
C5L2.
Although recent reports have identified a C5aR agonist
peptide as a ligand at C5L2 (16, 17), the mechanism of ligand
binding to C5L2 has not been reported. In this report, we
describe a systematic analysis of the role of the N terminus of
C5L2 in the interaction with ligands and demonstrate that
this domain has a critical role in binding to C5a des Arg but
not to C5a.
EXPERIMENTAL PROCEDURES
Cell Culture—RBL-2H3 and Chinese hamster ovary
(CHO)2 cells were routinely cultured in Dulbecco’s modified
Eagle’s medium  10% (v/v) fetal calf serum supplemented
with 400 mg/liter G-418 for transfected cells, at 37 °C, 5%
CO2. In experiments where NaClO3 was used to inhibit tyro-
sine sulfation, cells were grown for 5 days in low sulfate
Dulbecco’s modified Eagle’s medium/F12 (Sigma) supple-
mented with 10% (v/v) dialyzed fetal calf (Invitrogen) serum
and 10 mM NaClO3 (Sigma).
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Receptor Cloning and Expression—Mouse C5L2 cDNA was
kindly provided by Dr. Hui Tian, Amgen Inc. Human C5L2 was
cloned as previously described (15). All constructs were cloned
into pEE6 (Celltech) and transfected into CHO cells by stand-
ard electroporation protocols. After selection in G418, homog-
enous populations of cells were produced by two rounds of
fluorescence-activated cell sorting using rabbit polyclonal anti-
sera that recognize the N-terminal sequence of human, rat, or
mouse C5L2 on a BD Biosciences Vantage flow cytometer
(mouse, human) or cloning by limiting dilution (rat). RBL-2H3
cells expressingmouse C5aR were a generous gift fromDr. Jorg
Zwirner (Gottingen); CHO cells expressing human C5aR were
made as previously described (18). Rat C5aR, cloned from rat
liver using sequence Y09613 and rat C5L2 cDNA, a generous
gift from Dr. Vitaliy Gavrilyuk, (University of Illinois), were
subcloned into pEE6 for expression in CHO cells. The cDNA
for human C5aR with the mutations D15A, D18A, or Y14F in
pCDNA3.1 were generous gifts from Dr. Carla de Haas (Utre-
cht). A monoclonal antibody (M2; Sigma) that recognizes an
N-terminal FLAG tag sequence was used to sort the highest
50% of transfected cells in two rounds of fluorescence-activated
cell sorting.
Production of Peptides, Antibodies, andRecombinant Ligands—
Antiserum against a synthetic peptide analog of theN terminus
of human C5L2 (1–32) was prepared as described previously
(19) and affinity purified using the synthetic peptide. Com-
pounds 73 and 74 (non-peptidic antagonists) (20) and 3257 and
3261 (non-peptidic agonists) (21) at the human C5a receptor
are described in supplemental material. His6-tagged recombi-
nant ligands and peptides were synthesized as described previ-
ously (22).
Construction of Mutants of Human C5L2 N Terminus—Sub-
stitutionmutants (E9A,D12A,D15A,D18A,D22A,D25A,Y8F,
Y10F, Y13F) were made using Stratagene QuikChange kits
according to the manufacturer’s instructions and cloned into
pEE6 after authentication by DNA sequencing. A chimeric
C5L2, with the N terminus of hC5aR, substituting residues
1–32 (hC5L2) with 1–37 (hC5aR), was made by overlap exten-
sion using the primers shown in supplemental material. After
authentication by DNA sequencing, chimera C5aRNC5L2 was
cloned into pEE6 for transfection of CHO cells.
His6-C5a/C5a des Arg Binding Assays—The binding of
ligand to wild type and mutant C5L2 and C5aR was measured
using an indirect immunofluorescence method as previously
described (23, 24). Cells transfectedwith the appropriate recep-
tor (50,000/well of a 96-well microtiter plate) were incubated
with the stated concentrations of His6-tagged C5a or C5a des
Arg for 30 min at 4 °C in phosphate-buffered saline  0.1%
bovine serum albumin, 0.2% (w/v)NaN3 and thenwashed twice
with cold phosphate-buffered saline to remove unbound
ligand. Anti-His6 antibody (mouse IgG; Qiagen) was added (50
l at 2 g/ml) and incubated with the cells for 30 min at 4 °C.
After a further wash in phosphate-buffered saline, 50 l of flu-
orescein isothiocyanate anti-mouse IgG (Sigma) was used to
detect bound ligand using a FACSsort flow cytometer (BD Bio-
sciences). Binding was calculated as the percentage of positive
cells, i.e. with a fluorescent intensity higher than control cells
measured in the absence of ligand. Receptor affinities are
reported as EC50 values, calculated by non-linear regression
analyses using GraphPad Prism v4.0 (GraphPad Software, San
Diego, CA).
FIGURE 1. The binding of C5a and C5a des Arg to human and rodent C5L2 and C5aR. RBL and CHO cells transfected with human (A,D), mouse (B, E), or rat
(C, F) C5L2 (A–C) or C5aR (D–F) were incubated for 30 min with either a high (5000 nM), intermediate (50 nM), or low (5 nM) dose of His6-tagged C5a (solid bars)
orHis6-taggedC5adeArg (shadedbars) andbindingmeasuredusing indirect immunofluorescence, expressedaspercentof cellswith fluorescencehigher than
cells incubated without ligand. The bars (high to low concentrations shown from left to right) are means S.E. of three separate experiments performed in
duplicate.
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RESULTS
Rodent C5L2 Homologs Are Primarily C5a des Arg-binding
Proteins—Although human C5L2 has been well characterized,
ligand binding by rodent C5L2 has not previously been
reported. Rat, mouse, and human C5aR and C5L2 were
expressed in CHO cells (except for mouse C5aR, which was
expressed in RBL cells), and high expressing cell populations
were produced either by cell sorting or by cloning. His6-tagged
human, rat, andmouse C5a and C5a des Arg at a high, interme-
diate, or low dose (5000, 50, 5 nM) determined by the previously
reported ligand binding affinities of hC5L2 (15, 16) were
allowed to bind at 4 °C, followed by extensive washing. Surface-
bound ligand was then detected by indirect immunofluores-
cence using an anti-His6 monoclonal antibody. This method
measures only the ligand that remains bound after 1.5 h (i.e.
that has a slow off-rate) and soC5a desArg binding toC5aR, for
example, appears quite low (Fig. 1) and no binding of human
C3a or C3a des Arg to human C5L2 can be detected (data not
shown). However, the EC50 values for hC5a binding to both
hC5L2 (7 nM) and hC5aR (4 nM) (Table 1) are in close agree-
ment with previously published binding affinities obtained
using radiolabeled ligands,3 nM for both receptors (16). Sim-
ilarly, hC5a des Arg binding to hC5L2 and hC5aR produced
EC50 values of36 and527 nM (Table 3), again not dissimilar
to affinity values obtained indirectly using radio competition
assays, (12 and660 nM, respectively) (16). Thus, the ligand
binding assay employed here is a valid quantitative method for
the analysis of receptor affinities, with the advantage that it does
not require chemical modification of the ligand and so is used
here to facilitate the comparison of ligand binding to receptors
from different species.
It can be seen that C5L2 of all three species has an equal or
higher affinity (or slower off-rate) for C5a des Arg compared
with C5a. For the rodent species in particular, the lower
levels of C5a binding suggest that C5L2 is primarily a C5a des
Arg-binding protein, with a much lower propensity to bind
or retain C5a. Mouse C5L2 is still saturated at 5 nMmC5a des
Arg, whereas the binding of 5 nM mC5a is 50% maximal.
When the affinity of mC5L2 was determined more carefully,
using a wider range of ligand concentrations, the affinity for
mC5a was 4000-fold lower than mC5a des Arg (data not
shown). This is in contrast to mC5aR, which clearly shows a
preference for mC5a over mC5a des Arg (Fig. 1). For rat
C5L2, the difference is also marked, with the binding of 5 nM
rC5a reduced to almost undetectable levels but 5 nM rC5a
des Arg still at near-maximal binding (Fig. 1). The species of
C5a/C5a des Arg used also appears to show differences
between C5L2 and C5aR. Human C5L2 appears to show pro-
miscuous binding with little preference for same species
ligands, whereas human C5aR shows a higher degree of dis-
crimination. Mouse and rat C5L2, in contrast, bind human
C5a and C5a des Arg only weakly but show a clear preference
for C5a des Arg over C5a (Fig. 1).
A Panel of Synthetic Analogs of the C-terminal of C5a Are
More Potent Inhibitors at C5aR than at C5L2—For C5aR, the
full agonist potential of C5a is vested in only the C-terminal
decapeptide of C5a, which binds in the transmembrane bindingTA
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pocket.We have used a panel of peptidic and non-peptidic ana-
logs of the C5aC terminus to compare the characteristics of the
transmembrane binding pockets of C5L2 and C5aR. All the
analogs were capable of blocking the binding of 50 nM His6-
hC5a to hC5aR at statistically significant levels (Fig. 2A): F-
[OP(DCha)WR], YSFKPMPLaR, FKP(DCha)Cha(D-R)-CO2H,
FKP(DCha)Cha(D-R)-CONH2, 73, 74, 3261, 3257 (all 100 M),
W-54011 and YFKAChaChaL(D-F)R (both 10 M because of
limited solubility and toxicity, respectively). In contrast, these
inhibitors had very weak effects on His6-hC5a binding to
hC5L2 (Fig. 2B), and only 3257, 3261, and FKPDChaChaD-R-
CONH2 inhibited binding to a significant extent. 3257, 3261,
FKPDChaChaD-R-CO2H, and FKPDChaChaD-R-CONH2
could partly inhibit His6-hC5a des Arg binding to hC5L2 (Fig.
2C). The analogs were all ineffective at mC5L2, although only
mC5a des Arg binding was measured as mC5a binding levels
were too low for accurate assessment of inhibition (Fig. 2D).
Thus, despite the conservation of many of the same residues,
ligand binding to the transmembrane binding pockets of C5aR
and C5L2 is clearly different.
An Antibody Raised against the
N Terminus of Human C5L2
Inhibits C5a des Arg, but Not C5a,
Binding—To examine the role of
the N terminus of C5L2 in ligand
binding, a rabbit polyclonal anti-
serum, prepared using a synthetic
peptide with the N-terminal
sequence of human C5L2-(1–32)
(19), was used. The affinity-puri-
fied anti-serum was preincubated
at 0.28 mg/ml with hC5L2 before
the binding affinity for C5L2
ligands was measured. For hC5L2,
the high affinity binding of His6-
hC5a was not affected at all by
antibody pretreatment (p  0.62,
Student t test) but the affinity for
hC5a des Arg was decreased by
more than 370-fold (pEC50 values
significantly different, p 0.0006)
(Fig. 3. The lack of an effect on
hC5a binding suggests that the
antibody is blocking binding of
C5a des Arg by a specific mecha-
nism, possibly by hindering access
to key residues in the N-terminal
domain of C5L2.
Replacement of the C5L2 N-ter-
minal Domain with C5aR Sequence
Does Not Decrease Affinity for C5a
des Arg—The inhibition of hC5a des
Arg binding by anti-hC5L2 anti-
body implicates the N terminus in
ligand binding. The role of the
N-terminal domain was further
investigated by making a chimeric
form of hC5L2 with the N terminus
of hC5aR, substituting residues 1–32 (hC5L2) with 1–37
(hC5aR). After transfection and selection of CHOcells express-
ing similar levels of receptors, the binding affinity of His6-hC5a
and hC5a des Arg was measured (Fig. 4). The affinity of the
chimeric receptor, C5aRNC5L2, for hC5a was changed only
slightly (2-fold change relative to both parental receptors).
Interestingly, hC5a des Arg binding was also unaffected; the
affinity of C5aRNC5L2 was not significantly decreased (2-
fold) relative to hC5L2 although it was clearly higher than the
affinity for C5aR (15-fold). This finding suggests that the N
terminus is not the only determinant of the high affinity of
hC5L2 for hC5a des Arg.
Mutation of the C5L2 N Terminus Primarily Affects Binding
Affinity for C5a des Arg—The data from the chimeric receptor
suggested that common ligand binding elements were present
in the N termini of both C5aR and C5L2. To try and identify
these elements, we measured the binding affinities of C5L2
mutated at residues analogous to those previously shown to be
involved in C5a binding by C5aR: 6 acidic (E9A, D12A, D15A,
D18A, D22A, D25A) (Fig. 5, A and B, Table 1) and 3 tyrosine
FIGURE 2. The binding of analogs of the C terminus of C5a to human C5L2 and C5aR. CHO cells
transfected with either human C5aR (A) human C5L2 (B, C), or mouse C5L2 (D) were preincubated with
high doses (YFKAChaChaLD-FR, W-54011 10 M, remainder 100 M) of C5a analogs for 15 min and then
incubated for 30 min with 50 nM His6-tagged human C5a (A, B), human C5a des Arg (C), or mouse C5a des
Arg (D) and bound ligand quantified by indirect immunofluorescence, expressed as percent of binding to
cells in the absence of analogs. The bars aremeans S.E. of four to seven separate experiments performed
in duplicate. Significance of difference from 100 was assessed by one sample t test, *, p  0.5%; **, p 
0.5%; ***, p  0.05%.
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(Y8F, Y10F, Y13F) (Fig. 5, C and D, Table 2) residues in the N
terminus of hC5L2. The affinity for hC5a was either unchanged
or actually increased in all cases except D22A, where affinity
decreased by8-fold. In contrast, the affinity for hC5a des Arg
was significantly reduced in several cases: 3-fold (E9A), 11-fold
(D12A), 7-fold (D15A), 1000-fold (D22A), 125-fold (Y10F),
39-fold (Y13F). In all cases except D22A the lack of a reduction
in affinity for hC5a suggests that this effect on hC5a des Arg
binding is specific and not due simply to misfolding of mutant
receptors. C5a and C5a des Arg have quite distinct modes of
binding to C5L2 that involve different interactions with acidic
and tyrosine residues.
Mutation of the C5aRNTerminus Affects Binding Affinity for
BothC5a andC5a des Arg—Tocompare the effects ofmutating
acidic and tyrosine residues on C5L2 and C5aR, C5a and C5a
des Arg binding to CHO cells transfected with human C5aR
mutated at Asp-15, Asp-18, or Tyr-14 wasmeasured.Wild type
(WT)C5aR had a 95-fold lower affinity for C5a des Arg than for
C5a. All of themutants had significantly decreased affinities for
both C5a and C5a des Arg. Y14F had the largest decreases in
affinity, 76-fold (Table 3) and 23-fold for C5a and C5a des
Arg, respectively. For D15A, the decreases in affinity were 6-
and 5-fold and for D18A 3- and 8-fold.
Inhibition of Sulfotyrosine Formation Has Different Effects on
Ligand Binding by C5L2 and C5aR—Incubation of cells with
NaClO3 in low sulfate medium is a specific method for the
inhibition of tyrosine sulfation (25). CHO cells expressing
either hC5L2 or hC5aR were treated with 10 mM NaClO3, and
the binding affinities for C5a and C5a des Arg were measured.
Receptor expression, determined using specific antibodies, was
not significantly affected by this treatment (relative to
untreated controls, C5aR expression 115% 11; C5L2 expres-
sion 73%  15, mean  S.E., n  3). C5a binding to C5aR was
substantially inhibited by this treatment (maximal binding was
reduced to 24% of untreated control) (Fig. 6A), although C5a
des Arg binding was almost undetectable for treated and
untreated cells. Interestingly, this diminution of the maximal
binding was not due to changes in affinity (EC506 nM for both
untreated and treated cells), suggesting that a minority of the
C5aR retained high affinity binding sites after treatment. In
contrast, C5a binding toC5L2was completely unaffected (max-
imal binding was reduced by 5%) whereas maximal C5a des
Arg binding was reduced by27% (significantly different from
untreated control, p  0.031) but with no change in affinity.
This suggests that a majority of C5L2 is unaffected by NaClO3
treatment. Despite this relatively small effect, it is clear that C5a
des Arg binding is more sensitive than C5a binding to condi-
tions that are inhibitory for sulfation.
DISCUSSION
C5L2 is the most recently discovered anaphylatoxin recep-
tor and is the least well characterized. Although rodent
homologs of hC5L2 have been reported (12, 16) and a C5L2-
nullizygous mouse described (14), the ligand binding prop-
erties of these homologs have not yet been reported. We
show here that rat andmouse C5L2 have an even stronger pref-
erence for C5a des Arg than hC5L2, to such an extent that these
receptors might be considered as C5a des Arg rather than C5a
FIGURE 3. The effects of an antibody against the N terminus of human
C5L2 on ligand binding. CHO cells transfected with human C5L2 were
preincubated with phosphate-buffered saline (filled symbols) or 0.28
mg/ml of affinity-purified rabbit polyclonal antibody (open symbols)
raised against the N terminus of human C5L2 for 15 min and then incu-
bated for 30 min with His6-tagged human C5a (squares) or C5a des Arg
(triangles). Bound ligand was quantified by indirect immunofluorescence
and expressed as percent of maximal binding to cells, i.e. in the absence of
antibody. The data are means  S.E. of three separate experiments per-
formed in duplicate.
FIGURE 4. The binding of C5a and C5a des Arg to human C5L2, C5aR, and
anN-terminal chimera.CHOcells transfectedwith humanC5L2, C5aR, and a
chimera of human C5L2 with the N-terminal domain of C5aR (C5aRNC5L2)
were incubated for 30 min with His6-tagged C5a (A) or C5a des Arg (B) and
bound ligand quantified by indirect immunofluorescence, expressed as per-
cent of binding to cells in the absenceof analogs. Thedata aremeans S.E. of
three separate experiments performed in duplicate.
Interaction of Ligands with C5L2 and C5aR
3668 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 6•FEBRUARY 9, 2007
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
receptors. A recent study of the C5L2-nullizygous mouse used
only mC5a to stimulate intra-peritoneal accumulation of neu-
trophils and chemotaxis ofmC5L2-deficient bonemarrow cells
(14) and observed that the loss of C5L2 resulted in an increase
in the response to mC5a. It would be interesting to see if any
change in responsiveness to the high affinity ligand for mC5L2,
mC5a des Arg, occurs in C5L2-nullizygous animals. Our data
also suggest that caution should be used when C5a from one
species is used to bind to C5L2 or C5aR from another species.
The use of human C5a/C5a des Arg in mice could lead to the
erroneous conclusion that mC5L2 did not bind these ligands
with high affinity.
The ligand binding sites on C5aR have been mapped by a
number of methods. Antibodies directed against the N-termi-
nal domain have been shown to inhibit the binding of C5a (26,
27), and deletion of the N terminus also prevents C5a binding
(6, 7). A chimeric form of C5aR with the N terminus of the
receptor for the closely related anaphylatoxin C3a, C3aR, also
loses the ability to bind C5a (28). However, in all of these cases,
peptide analogs of the C terminus of C5a have still been able to
activate the receptor, indicating the presence of an additional
binding site. These data have led to the two-sitemodel of recep-
tor activation that proposes a primary high affinity contact
between basic residues in the core of C5a and acidic residues in
the N terminus of C5aR, and a sec-
ondary interaction between the C
terminus of C5a and a binding
pocket formed by hydrophobic
residues in the transmembrane
domains and charged residues at the
bases of the extracellular loops (11).
It is interesting to note that C3aR
has a similar two-site binding
modality except that the primary
site is located on an enlarged second
extracellular loop rather than at the
N terminus (28, 29). The secondary
binding site on C3aR is apparently
formed in the same way as the C5aR
site, as many of the hydrophobic
and charged residues proposed to
form this site are conserved and a
chimeric C3aR with the N terminus
of C5aR both binds to, and is acti-
vated by, C5a. It is therefore very
interesting that ligands that might
bind at the secondary site of C5L2
have very little ability to block C5a
or C5a des Arg binding to C5L2.
The lack of effect of the cyclic pep-
tide, F-[OP(DCha)WR], on C5a
FIGURE 5. The binding of C5a and C5a des Arg to human C5L2mutated at N-terminal acidic and tyrosyl
residues. CHO cells transfected with wild type (WT, broken line) or mutant human C5L2 (solid lines) were
incubated for 30min with His6-tagged C5a (A, C) or C5a des Arg (B,D) and bound ligand quantified by indirect
immunofluorescence, expressed as percent of binding of 1 M C5a to cells expressing each mutant C5L2. The
data are means S.E. of n (see Table 1) separate experiments performed in duplicate.
TABLE 2
The binding of C5a and C5a des Arg to C5L2mutated at N-terminal tyrosyl residues
pEC50 significantly different fromWT-C5L2: * 5%; ** 0.5%; *** 0.005% (two-tailed t test).
Receptor Y8F Y10F Y13F
Ligand EC50a pEC50b nc EC50 pEC50 n EC50 pEC50 n
C5a 4.18 8.38 0.06* 8 7.70 8.11 0.08ns 8 5.23 8.28 0.06ns 8
C5a desArg 79.7 7.10 0.10* 8 4490 5.35 0.44*** 8 1420 5.85 0.16*** 8
a EC50, concentration (nM) resulting in 50% of the maximum binding.
b pEC50,log10EC50.
c n, number of separate experiments performed in duplicate.
TABLE 3
The binding of C5a and C5a des Arg to C5aRmutated at N-terminal acidic and tyrosyl residues
pEC50 significantly different fromWT-C5L2: * 5%; ** 0.5%; *** 0.005% (two-tailed t test).
Ligand WT D15A D18A Y14FEC50a pEC50b nc EC50 pEC50 n EC50 pEC50 n EC50 pEC50 n
C5a 5.52 8.26 0.05 8 34.1 7.47 0.14*** 4 17.0 7.71 0.06*** 8 41.8 7.38 0.06*** 6
C5a desArg 527 6.28 0.14 8 2880 5.541** 0.15 4 4390 5.36 0.12*** 8 12100 4.92 0.06*** 6
a EC50, concentration (nM) resulting in 50% of the maximum binding.
b pEC50,log10EC50.
c n, number of separate experiments performed in duplicate.
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binding by C5L2 has already been noted (17) and is confirmed
here. FKP(DCha)Cha(D-R), an agonist at C5aR that is reported
to bind with low affinity to C5L2 (16, 17), does not inhibit C5a
binding toC5L2 even at 100M, 4-fold higher than the reported
EC50 for C5L2, although we do see a significant inhibition of
C5a des Arg binding. The reason for this apparent discrepancy
may be the relatively high dose of C5a (50 nM) thatwe employed
for this assay compared with the much lower dose used in the
previous report (0.1 nM). However, we clearly see a significant
inhibition of binding to C5aR at this dose of C5a, suggesting
that C5L2 has a much lower affinity for FKP(DCha)Cha(D-R)
than C5aR. It is interesting to note that of the 6 C5aR agonists
tested, 4/6 and 2/6 were capable of inhibiting C5a des Arg and
C5a binding to C5L2, respectively, whereas none of the 4 antag-
onists had any significant effect on either ligand. This suggests
that the secondary binding site on C5L2, despite the conserva-
tion of residues, might resemble only the agonist binding con-
formation of C5aR. It is unclear from our data whether the lack
of effect of the analogs is due to their low affinity for C5L2 or
whether the interaction between C5a/C5a des Arg and the sec-
ondary site on C5L2 is not critical for high affinity binding. The
lack of signaling of C5L2 after ligand binding does suggest that
the transmembrane site is not involved in C5a/C5a des Arg
binding and that strong interactions with ligand are made in
other domains of C5L2.
We also observed a difference between the roles of the N
termini in hC5aR and hC5L2 in ligand binding. In contrast to
hC5aR (26), antibodies that bind to the N-terminal domain of
hC5L2 could significantly inhibit hC5a des Arg, but not C5a,
binding. Although this could be due to the 9-fold difference in
affinity of hC5L2 for hC5a and hC5a des Arg, as measured by
immunofluorescence detection of the His6 tag, the apparent
affinity shift for hC5a des Arg in the presence of antibody is
373-fold, larger than would be expected on the basis of affinity
for hC5a des Arg alone. We also observed a selective inhibition
of hC5a des Arg binding to hC5L2 when we treated transfected
cells with the chemotaxis inhibitor protein of Staphylococcus
aureus (CHIPS) at a concentration that completely inhibited
hC5a binding to hC5aR.3 CHIPS binds to hC5aR at a site in the
N terminus that involves acidic residues Asp-10, Asp-15, and
Asp-18 and is a competitive inhibitor of hC5a binding (30). The
differential role of the N terminus was also observed when a
chimeric hC5L2 was produced that expressed the N-terminal
domain of hC5aR. The chimeric receptor had an affinity for
hC5a des Arg that was not significantly different from hC5L2
but that was significantly higher than hC5aR. As expected, the
affinity for hC5a was similar for all three receptors, as was the
ratio of affinities for hC5a/hC5a des Arg; for hC5aR, this was
100, whereas hCL2 and C5aRNC5L2 had ratios of 8 and 5,
respectively. This suggests that, although the N terminus is
involved in the binding of hC5a des Arg by hC5L2, there is a
significant contribution from additional binding sites. For
C5aR, residues 1–18 of the N terminus have been suggested to
interact with the extracellular loops to achieve the correct con-
formation for ligand binding at residues 21–30 of the N termi-
nus (8). A similar mechanism may occur for C5L2: The anti-
body epitope is currently unknown, but CHIPS binds to
residues 1–18 of C5aR (30) and so it is possible that the inhibi-
tion of C5a des Arg binding by these molecules is indirect, due
to the disruption of a complex binding surface.
As the N termini of hC5aR and hC5L2 can be exchanged
with little effect on ligand binding, it is likely that a similar
array of acidic and/or sulfated residues is present in both
receptors. The role of the N-terminal acidic and tyrosyl res-
idues in hC5L2 was investigated in more detail by point
mutagenesis. Similar studies have previously been per-
formed on hC5aR: hC5aR(D15,16,18,21N) showed a 40-fold
decrease in hC5a affinity and hC5aR(D10,15,16,18,21N)
showed a 133-fold reduction (7); single mutants of D10N and
D27N or a double mutant (D21N,D27N) had no effect on hC5a
binding, whereas the multiple substitutions hC5aR(D10,15,16)
or hC5aR(D15,16,21,27) showed no detectable hC5a binding
(31). Similarly, an NMR study on the hC5aR N terminus high-
lighted the importance of residues 21–30 in hC5a binding (8).
Thus, we might expect single substitutions to have only small
effects on ligand binding by hC5L2.Wemutated 6 acidic (5 Asp
and 1Glu) residues in the region of theN terminus analogous to
3 A. J. Wright, A. Higginbottom, D. Philippe, A. Upadhyay, S. Bagby, R. C. Read,
L. J. Partridge, and P. N. Monk, manuscript in preparation.
FIGURE 6. The binding of C5a and C5a des Arg to human C5L2 and C5aR
after treatmentwith sulfation inhibitors.CHO cells transfectedwith either
C5L2 (A) or C5aR (B) were grown for 5 days in normal medium () or low
sulfate Dulbecco’s modified Eagle’s medium/F12 supplemented with 10 mM
NaClO3 (). Cells were incubated with His6-tagged C5a or C5a des Arg and
bound ligand quantified by indirect immunofluorescence, expressed as per-
cent of 500 nM C5a binding to cells. The data are means S.E. of three sepa-
rate experiments performed in duplicate.
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the primary ligand-binding domain of hC5aR and found that
only one, Asp-22, caused a significant disruption of hC5a bind-
ing (8-fold decrease in affinity). This residue does not align
with an Asp in hC5aR (Asn-23 is a likely analog), and so the
effects ofmutation at this position cannot be directly compared
in the two receptors. In contrast to the moderate effects on
hC5a, four of the mutants, E9A, D12A, D15A, and D22A,
caused substantial reductions in the binding of hC5a des Arg.
These mutants had hC5a/C5a des Arg affinity ratios of 30, 43,
81, and 1000, respectively, which were much larger than for
WT hC5L2 (5). Clearly, hC5a des Arg binding has a greater
dependence on these acidic residues than hC5a. In contrast, the
mutation of two acidic residues on hC5aR, Asp-15 and Asp-18,
had similar effects on both hC5a and hC5a des Arg binding.We
alsomutated tyrosyl residues in hC5L2 thatmay bemodified by
the addition of sulfate moieties. In hC5aR, Tyr-11 and Tyr-14
have been shown to be sulfated; the mutant Y11F shows almost
complete loss of C5a binding and Y14F shows 50% loss of
binding affinity, whereas mutation of Tyr-8 has no effect on
either sulfation or ligand binding (9). Here, we confirmed that
mutation of Tyr-14 to Phe could cause a substantial loss of
affinity of hC5aR for C5a and also showed that C5a des Arg
binding could be similarly affected. In contrast, mutation of
Y10F or Y13F on hC5L2 (the analogous residues to Tyr-11 and
Tyr-14 of hC5aR) had no significant effect on hC5a binding but
could substantially inhibit hC5a des Arg binding (hC5a/hC5a
des Arg binding ratios of 583 and 272, respectively). The
mutant Y8F had a much smaller effect on binding (ratio of
19). The possibility that ligand/receptor interactions occur
through the aromatic moiety of the Tyr-10 and Tyr-13 is not
explored by substitution with phenylalanine. However, as the
Y14F substitution in C5aR largely inhibits C5a binding, the
importance of these potential aromatic interactions is clearly
different for the two receptors. The inhibition of tyrosine sul-
fation by 16 h of growth in low sulfate medium supplemented
with NaClO3 has been shown to significantly inhibit ligand
binding to CCR5 (32). C5aR was very sensitive to these condi-
tions, whereas C5L2 was muchmore resistant even after 5 days
of growth in NaClO3-containing medium. This resistance sug-
gests a much slower turnover of C5L2 relative to C5aR or that
sulfation is largely irrelevant in the formation of the ligand
binding site on C5L2. These possibilities are currently under
investigation. However, the sensitivity of C5a des Arg binding
relative to C5a is further evidence of a greater role of N-termi-
nal residues in C5a des Arg binding.
In conclusion, we have shown that, although ligand binding
by C5L2 shares some common features with C5aR, there are
also unique properties with the N termini of these receptors
apparently having quite different binding roles. Strikingly,
C5L2 appears to use a distinctly different mechanism from
C5aR to bind to its two high affinity ligands, C5a and C5a des
Arg.
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SUPPLEMENTAL MATERIAL  
Structures of the C5a Antagonists 
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W-54011 73 74 
 
Synthesis: 
73: Dibenzylamine was treated with biphenyl-2-carbonyl chloride in a 2 phase mixture of 
dichloromethane and 0.5 M NaOH. After stirring for 10 min the dichloromethane layer was 
evaporated and the product was recrystallised from EtOAc/hexane giving white needles. 
 
74: Reductive amination of 4-isopropylaniline with 4-dimethylaminobenzaldehyde using sodium 
cyanoborohydride in methanol gave 4-dimethylaminobenzyl-4'-isopropylaniline as a pale yellow 
solid after flash chromatography. Treatment with 2,6-dimethylphenylisocyanate in dichloromethane 
at room temp for 5 min gave the urea derivative as a white solid after flash chromatography. 
 
C5a Agonists 
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3261 3257 
 
IC50 for 3261 was reported to be 300 nM (1).  
 
Production of chimeric C5L2 protein 
Primers: 
5’ C5aR   AAGCTTGCCGCCACCATGAACTCCTTCAATTATACCACCC 
3’ C5L2     GGGCCCGAATTCCTACACCTCCATCTCCGAGGAC 
5’ C5aRNC5L2  GCGCAGCGGGTCTGGAACACGCAGCGT 
3’ C5aRNC5L2  GTTCCAGACCCGCTGCGCGTGGCCC  
 
 
1. De Laszlo, S. E., Allen, E. E., Li, B., Ondeyka, D., Rivero, R., Malkowitz, L., Molineaux, C., 
Siciliano, S. J., and Springer, M. S. (1997) Bioorganic & Medicinal Chemistry Letters 7(2), 
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